#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Type IIa hyperlipidaemia Congenital generalised lipodystrophy Restless legs syndrome Nephrotic syndrome VEXAS syndrome Hodgkin's disease refractory Cardiac failure acute Fatty acid oxidation disorder Primary mediastinal large B-cell lymphoma Prader-Willi syndrome Marginal zone lymphoma Inflammatory myofibroblastic tumour Marginal zone lymphoma refractory Systemic sclerosis pulmonary Congenital disorder of glycosylation More trials…

    Learn about Rare Diseases

    Glycogen storage disease type II – Life with Disease Adrenogenital syndrome – Basic Information Chronic granulomatous disease Andersen-Tawil syndrome – Treatment Mucopolysaccharidosis III – Basic Information Leiomyosarcoma recurrent – Trials in Disease Wolfram syndrome – Life with Disease Von Willebrand’s disease – Diagnostics Focal segmental glomerulosclerosis Nephrotic syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    USNOFLAST Anifrolumab Oxybutynin Mps-215 Hydroxi-Methionine Calcium Emapalumab Tebipenem Pivoxil Hydrobromide Codeine Phosphate Hemihydrate VGA039 Caspofungin Acetate Kk8123 [14C] DC-806 CIRTUVIVINT Crd-4730 Bt-001 Hydrocortisone Acetate Simoctocog Alfa Trifluridine Prednisolone Sodium Phosphate STREPTOCOCCUS VIRIDANS More therapies…

    Learn about Your Condition

    Malformation venous Peripheral ischaemia Obstructive pancreatitis Dermatitis atopic Febrile neutropenia Uterine leiomyoma Colitis Oesophageal achalasia Bronchiolitis Spinal cord injury cervical Marginal zone lymphoma Thyroid cancer Haematological infection Sinusitis bacterial Depression More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Schwerpunktpraxis fuer Gynakologische Onkologie

Schwerpunktpraxis fuer Gynakologische Onkologie

Domgasse 1, Fürstenwalde, 15517, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Tamoxifen
    • Anastrozole
    • Elacestrant
    Austria Belgium Czechia Denmark Finland France +9

  • Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Breast cancer female
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Fulvestrant
    Germany

  • Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer stage III
    • Breast cancer
    Investigated Drugs:
    • Capecitabine
    • Carboplatin
    • Cisplatin
    Austria Belgium France Germany Ireland Spain

  • Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Ribociclib
    Germany

  • Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Atezolizumab
    • Carboplatin
    • Cyclophosphamide
    Germany Spain

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!